Horizon's Genmab drug gets blockbuster status
![Rare eye disease Graves' opthalmopathy has been a big money maker for Horizon Therapeutics. | Photo: Marijan Murat/AP/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13429541.ece/ALTERNATES/schema-16_9/20029633891466-1920x1080we.jpg)
Horizon therapeutics has sold more than twice as much of its drug Tepezza during the first nine months of 2021 than it did during the same period last year, its Q3 report reveals.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab sales of Darzalex exceed expectations in Q3
For subscribers
New Genmab/Seagen drug will cost up to USD 120,000
For subscribers